United Kingdom · Question · Written question
HL HL14040
Liothyronine
Introduced
9 March 2021
Last action
17 March 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
17 March 2021
Summary
To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 4 March (HL13668), what comparison they have made of the cost of Liothyronine (T3) in (1) the UK, and (2) EU member states; and what assessment they have made of any such co
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
9 March 2021
Written question
To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 4 March (HL13668), what comparison they have made of the cost of Liothyronine (T3) in (1) the UK, and (2) EU member states; and what assessment they have made of any such co
Source: Lords
17 March 2021
Answer
The Department has made no such comparison or assessment. All United Kingdom marketing authorisation holders of liothyronine are obliged to ensure that the product complies with the minimum standard as specified in the British Pharmacopoeia monograph for ...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-03-09/HL14040
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1301011
- uk · wq-1301011 · source updated 17 March 2021